Batten Disease Treatment Market Business Segmentation By Revenue And Structure Forecast 2027

 

Batten disease is really a rare, inherent, and fatal autosomal recessive neural disorder that begins in the childhood but usually takes many years to show symptoms. Batten disease is one of many approximately 50 diseases that fall under the sounding lysosome shortage disorders. The batten disease also referred as Neuronal ceroid Lipofuscinoses (NCLs), which is a class of life-limiting genetic neurogenerative diseases which are caused as a result of abnormality of genes leading to their inability to synthesize required protein.

In line with the Centers for Disease Control and Prevention (CDC), Batten disease is observed in 2-4 per 100,000 live births in the United States on an average. The Batten Disease Treatment Market although is rare but has high incidence rates in Finland, Sweden, and the rest of the Europe as compared to remaining portion of the world. In line with the Batten Disease Support and Research Association, the batten disease has often been encountered in more than one children of exactly the same family. The Daily News and Analysis article published in June 2016 implies that, over 20 million children in India suffer with rare diseases, having expensive treatments.

This disease is characterized by malfunctioning of body, which often appears around the age of 2-10 with symptoms, such as for instance seizures or gradual onset of vision problem. The first signs may show subtle changes in behavior and learning, however over time, the little one is suffering from mental impairment, progressive loss in sight, speech and motor reactions, worsening seizures, eventually leading to blindness dementia, and finally death.

The rising incidence of the batten disease without effective treatment option for the prevention and cure of the disease is the primary driver for batten disease market, as a result of which several companies are vying to enter into the untapped global batten disease treatment market. However, the possible lack of awareness among manufacturers and patient population along with unavailability of treatment for this disease are greatly hampering the growth of the global batten disease treatment market.